RT Journal Article
SR Electronic
T1 Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.24.21262564
DO 10.1101/2021.08.24.21262564
A1 Agrawal, Saaket
A1 Wang, Minxian
A1 Klarqvist, Marcus D. R.
A1 Shin, Joseph
A1 Dashti, Hesam
A1 Diamant, Nathaniel
A1 Choi, Seung Hoan
A1 Jurgens, Sean J.
A1 Ellinor, Patrick T.
A1 Philippakis, Anthony
A1 Ng, Kenney
A1 Claussnitzer, Melina
A1 Batra, Puneet
A1 Khera, Amit V.
YR 2021
UL http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262564.abstract
AB For any given level of overall adiposity – as commonly quantified by body mass index (BMI) within clinical practice – individuals vary considerably in fat distribution. We and others have noted that increased visceral fat (VAT) is associated with increased cardiometabolic risk, while gluteofemoral fat (GFAT) may be protective. Familial partial lipodystrophy (FPLD) – often caused by rare variants in the LMNA gene – represents an extreme example of this paradigm, leading to a severe shift to visceral fat with subsequent insulin resistance and adverse metabolic profile. By contrast, the inherited basis of body fat distribution in the broader population is not fully understood. Here, we studied up to 38,965 UK Biobank participants with VAT, abdominal subcutaneous (ASAT), and GFAT volumes precisely quantified using abdominal MRI. Because genetic associations with these raw depot volumes were largely driven by variants known to affect BMI, we next studied six phenotypes of local adiposity: VAT adjusted for BMI (VATadjBMI), ASATadjBMI, GFATadjBMI, VAT/ASAT, VAT/GFAT, and ASAT/GFAT. We identify 178 unique loci associated with at least one adiposity trait, including 29 newly-identified loci. Rare variant association studies extend prior evidence of association for PDE3B as an important modulator of fat distribution. Sex-specific analyses of local adiposity traits noted overall higher estimated heritability in females, increased effect sizes for identified loci, and 25 female-specific associations. Individuals in the extreme tails of fat distribution phenotypes were highly enriched for predisposing common variants, as quantified using polygenic scores. Taking GFATadjBMI as an example, individuals with extreme values were 3.8-fold (95%CI 2.8 to 5.2) more likely to have a polygenic score within the top 5% of the distribution. These results – using more precise and BMI-independent measures of local adiposity – confirm fat distribution as a highly heritable trait with important implications for cardiometabolic health outcomes.Competing Interest StatementM.D.R.K., A.P, and P.B. are supported by grants from Bayer AG applying machine learning in cardiovascular disease. P.T.E. receives sponsored research support from Bayer AG and IBM and has consulted for Bayer AG, Novartis, MyoKardia and Quest Diagnostics. A.P. is also employed as a Venture Partner at GV and consulted for Novartis; and has received funding from Intel, Verily and MSFT. K.N. is an employee of IBM Research. P.B serves as a consultant for Novartis. A.V.K. has served as a scientific advisor to Sanofi, Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Verve Therapeutics, Silence Therapeutics, Veritas International, Color Health, Third Rock Ventures, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; and received a sponsored research agreement from the Novartis Institute for Biomedical Research. Funding StatementThis work was supported by the Sarnoff Cardiovascular Research Foundation Fellowship (to S.A.), student scholarships from the Dutch Heart Foundation and the Amsterdams Studentenfonds (S.J.J.), grants 1K08HG010155 and 1U01HG011719 (to A.V.K.) from the National Human Genome Research Institute, a Hassenfeld Scholar Award from Massachusetts General Hospital (to A.V.K.), a Merkin Institute Fellowship from the Broad Institute of MIT and Harvard (to A.V.K.), and a sponsored research agreement from IBM Research to the Broad Institute of MIT and Harvard (to P.T.E., P.B., A.V.K.). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mass General Brigham institutional review board; UK Biobank application #7089.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw UK Biobank data is made available to researchers from universities and other research institutions with genuine research inquiries, following IRB and UK Biobank approval. Full GWAS summary statistics for each of the nine adiposity traits in sex-combined and sex-stratified analyses will be made available for download from the Broad Institute Cardiovascular Disease Knowledge Portal under the "Downloads" tab at http://www.broadcvdi.org/ at the time of publication.